Search Results - "Drago, Joshua Z."

Unlocking the potential of antibody–drug conjugates for cancer therapy by Drago, Joshua Z., Modi, Shanu, Chandarlapaty, Sarat

“…Nine different antibody–drug conjugates (ADCs) are currently approved as cancer treatments, with dozens more in preclinical and clinical development. The…”
Get full text

Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions by Ferraro, Emanuela, Drago, Joshua Z, Modi, Shanu

“…The development of anti-HER2 agents has been one of the most meaningful advancements in the management of metastatic breast cancer, significantly improving…”
Get full text

Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis by Moss, Nelson S., Singh, Jolene M., Reiner, Anne S., Drago, Joshua Z., Modi, Shanu, Seidman, Andrew D., Chandarlapaty, Sarat, Ross, Dara S.

“…The HER2-directed antibody-drug conjugate trastuzumab deruxtecan is active against lower levels of HER2 expression than prior-generation therapies. The rate of…”
Get full text

Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer by Mai, Nicholas, dos Anjos, Carlos H., Razavi, Pedram, Safonov, Anton, Patil, Sujata, Chen, Yuan, Drago, Joshua Z., Modi, Shanu, Bromberg, Jacqueline F., Dang, Chau T., Liu, Dazhi, Norton, Larry, Robson, Mark, Chandarlapaty, Sarat, Jhaveri, Komal

“…After disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen…”
Get full text

Beyond HER2: Targeting the ErbB receptor family in breast cancer by Drago, Joshua Z., Ferraro, Emanuela, Abuhadra, Nour, Modi, Shanu

“…•Prior efforts to target the ErbB receptor family beyond HER2 have been inadequate.•Novel therapeutic approaches such as antibody-drug conjugates hold…”
Get full text

ADCs or: How I Learned to Stop Worrying and Love Chemotherapy by Gupta, Avantika, Drago, Joshua Z, Chandarlapaty, Sarat

“…Antibody-drug conjugates are transforming cancer treatment, and payload characteristics are emerging as crucial determinants of clinical activity. As…”
Get more information

Targeting Apoptosis: A New Paradigm for the Treatment of Estrogen Receptor-Positive Breast Cancer by Drago, Joshua Z, Chandarlapaty, Sarat, Jhaveri, Komal

“…Standard treatment for estrogen receptor-positive metastatic breast cancer involves antiestrogen therapy used alone or in combination with inhibitors of CDK4/6…”
Get more information

FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR + ) Breast Cancer by Drago, Joshua Z, Formisano, Luigi, Juric, Dejan, Niemierko, Andrzej, Servetto, Alberto, Wander, Seth A, Spring, Laura M, Vidula, Neelima, Younger, Jerry, Peppercorn, Jeffrey, Yuen, Megan, Malvarosa, Giuliana, Sgroi, Dennis, Isakoff, Steven J, Moy, Beverly, Ellisen, Leif W, Iafrate, A John, Arteaga, Carlos L, Bardia, Aditya

“…While amplification has been described in breast cancer, the optimal treatment approach for -amplified (FGFR1 ) metastatic breast cancer (MBC) remains…”
Get full text

Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate Cancer by Drago, Joshua Z, Gönen, Mithat, Thanarajasingam, Gita, Sacks, Chana A, Morris, Michael J, Kantoff, Philip W, Stopsack, Konrad H

“…Abstract Background Safety is a central consideration when choosing between multiple medications with similar efficacy. We aimed to evaluate whether adverse…”
Get full text

A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA -Mutated HER2-Positive Metastatic Breast Cancer by Jhaveri, Komal, Drago, Joshua Z, Shah, Payal Deepak, Wang, Rui, Pareja, Fresia, Ratzon, Fanni, Iasonos, Alexia, Patil, Sujata, Rosen, Neal, Fornier, Monica N, Sklarin, Nancy T, Chandarlapaty, Sarat, Modi, Shanu

“…Activating mutations in promote resistance to HER2-targeted therapy in breast cancer; however, inhibition of PI3K alone leads to escape via feedback…”
Get full text

The Harm in Kratom by Drago, Joshua Z., Lane, Bennett, Kochav, Jonathan, Chabner, Bruce

“…A case of severe hepatic toxicity associated with the use of kratom, a plant derivative increasingly used as a psychostimulant, is discussed…”
Get full text

Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome by Schwartz, Christopher J, da Silva, Edaise M, Marra, Antonio, Gazzo, Andrea M, Selenica, Pier, Rai, Vikas K, Mandelker, Diana, Pareja, Fresia, Misyura, Maksym, D'Alfonso, Timothy M, Brogi, Edi, Drullinsky, Pamela, Razavi, Pedram, Robson, Mark E, Drago, Joshua Z, Wen, Hannah Y, Zhang, Liying, Weigelt, Britta, Shia, Jinru, Reis-Filho, Jorge S, Zhang, Hong

“…Lynch syndrome is defined by germline pathogenic mutations involving DNA mismatch repair (MMR) genes and linked with the development of MMR-deficient colon and…”
Get full text

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study by Drago, Joshua Z, Lawrence, Donald, Livingstone, Elisabeth, Zimmer, Lisa, Chen, Tianqi, Giobbie-Hurder, Anita, Amann, Valerie C, Mangana, Joanna, Siano, Marco, Zippelius, Alfred, Dummer, Reinhard, Goldinger, Simone M, Sullivan, Ryan J

“…BRAF and MEK kinase inhibitors can be highly effective in treating BRAF-mutant melanomas, but their safety and activity in patients with active/symptomatic…”
Get full text

EGFR-directed antibodies promote HER2 ADC internalization and efficacy by Gupta, Avantika, Michelini, Flavia, Shao, Hong, Yeh, Celine, Drago, Joshua Z., Liu, Dazhi, Rosiek, Eric, Romin, Yevgeniy, Ghafourian, Negin, Thyparambil, Sheeno, Misale, Sandra, Park, Wungki, de Stanchina, Elisa, Janjigian, Yelena Y., Yaeger, Rona, Li, Bob T., Chandarlapaty, Sarat

“…Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor receptor 2 (HER2)-targeting antibody drug conjugate that has remarkable activity in…”
Get full text

Adverse event profiles of apalutamide, enzalutamide, and darolutamide in SPARTAN, PROSPER, and ARAMIS: How confident are we about which drug is safest? by Drago, Joshua Z., Kantoff, Philip W., Stopsack, Konrad H.

“…Abstract only 318 Background: Apalutamide, enzalutamide, and darolutamide were approved for non-metastatic castration-resistant prostate cancer (nmCRPC) based…”
Get full text

Abstract OT2-04-01: Circulating tumor DNA-guided adaptive therapy escalation in ER+ MBC: A phase 1b study with letrozole, palbociclib and onapristone ER by Drago, Joshua Z, Walsh, Elaine M, Gonen, Mithat, Berger, Michael F, Robson, Mark E, Chandarlapaty, Sarat, Razavi, Pedram, Jhaveri, Komal

“…Background: Extended release onapristone (onapristone ER) is a progesterone receptor (PR) antagonist that inhibits hormone-mediated PR activation and…”
Get full text

Detection of subthreshold microsatellite instability in breast cancer: An ongoing investigation by Drago, Joshua Z., Latham, Alicia, Modi, Shanu, Razavi, Pedram, Stadler, Zsofia Kinga, Robson, Mark E.

“…Abstract only 1089 Background: Microsatellite instability (MSI) and mismatch repair deficiency (MMRd) can occur sporadically in solid tumors across histologic…”
Get full text

HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers by Drago, Joshua Z., Pareja, Fresia, Jhaveri, Komal L., Walsh, Elaine M., Ku, Geoffrey Yuyat, Maron, Steven Brad, Janjigian, Yelena Y., Robson, Mark E., Reis-Filho, Jorge S., Modi, Shanu, Razavi, Pedram, Chandarlapaty, Sarat

“…1052 Background: T-DXd is a HER2-targeted antibody drug conjugate approved for treatment of advanced HER2-positive breast and gastroesophageal cancers and…”
Get full text

Personalized circulating tumor DNA for minimal residual disease and dynamic assessment in patients undergoing neoadjuvant chemotherapy for breast cancer: Preliminary analysis from MSK-LINC by Kim, Hong-Kyu, An, Julia Ah-Reum, Smith, Christopher Gareth, KIM, Jisun, Cabel, Luc, Moiso, Enrico, Ferraro, Emanuela, Safonov, Anton, Nelson, Konner, Szuhany, Kathleen, Drago, Joshua Z., Norton, Larry, Xu, Amy, Scher, Howard I., Chandarlapaty, Sarat, Khan, Atif J., Li, Bob T., Robson, Mark E., Plitas, George, Razavi, Pedram

“…3049 Background: Identification of minimal residual disease (MRD) with circulating tumor DNA (ctDNA) in pts with early-stage breast cancer holds promise to…”
Get full text

Abstract P2-13-19: Statin modulation of antibody drug conjugate activity in breast cancer models and patients by Drago, Joshua Z, Pereira, Patricia R, Safonov, Anton, Marra, Antonio, Rao, Yi, Liu, Bo, Ahmed, Mehnaj, Modi, Shanu, Reis-Filho, Jorge, Robson, Mark, Montemurro, Filippo, Razavi, Pedram, Lewis, Jason S, Chandarlapaty, Sarat

“…Background: Membrane HER2 expression levels strongly influence the activity of anti-HER2 therapies directed at the HER2 extracellular domain (1,2). Tumoral…”
Get full text